Cinclus Pharma Seeks $117 Million Valuation in Stockholm IPO (1)

Cinclus Pharma Holding AB plans to list on Nasdaq Inc. in Stockholm next week in what will be the first initial public offering by a health-care company on Sweden’s main stock market since 2019.

“The window for IPO’s is starting to open,” Cinclus Chief Executive Officer Christer Ahlberg said in an interview. “There’s no reason to wait. We want to get started with phase 3 as soon as possible.”

The Swedish bio-pharmaceutical firm hopes to raise 787 million Swedish kronor ($74.4 million) at a 1.24 billion kronor valuation, according to a statement on Monday. The first day of trading is ...